Pre-Test Agitation in Alzheimer’s Dementia: Progress for an Age - Old Problem Pre-Test Agitation occurs in approximately what percentage of patients with Alzheimer’s disease? 56% 66% 76% 86% Unsure Which of the following survey-based screening and diagnostic tools evaluates both the frequency of and care partner reaction to agitated behaviors occurring in patients with Alzheimer’s dementia over a 2-week period? Agitated Behavior in Dementia (ABID) Cohen-Mansfield Agitation Inventory (CMAI) Neuropsychiatric Inventory (NPI) Patient Health Questionnaire (PHQ) Unsure Which of the following statements regarding brexpiprazole is TRUE? 4 mg and 5 mg formulations significantly reduced CMAI total and CGI-S, as related to agitation A strong binding affinity is present for dopamine, norepinephrine, and serotonin receptors High rates of adverse events may occur with treatment, but cognitive decline is mitigated It is a first-generation antipsychotic agent available for the treatment of anxiety disorders Unsure Which of the following types of therapeutics carry a black box warning for treatment of patients with Alzheimer’s dementia due to severe and acute cardiovascular adverse events, but, due to their effectiveness against agitation, are still recommended in patients with severe symptoms that endanger patient and caregiver safety, well-being, and quality of life? Antidepressants Antipsychotics Anxiolytics Mood stabilizers Unsure Please rate your ability to incorporate patients and care partners in decisions related to the management of agitation in Alzheimer’s dementia. Excellent Very good Good Fair Poor
